[go: up one dir, main page]

AR066086A1 - Derivados de dihidro-benzo (b)(1,4)diazepin-2-ona-sulfonamida - Google Patents

Derivados de dihidro-benzo (b)(1,4)diazepin-2-ona-sulfonamida

Info

Publication number
AR066086A1
AR066086A1 ARP080101574A ARP080101574A AR066086A1 AR 066086 A1 AR066086 A1 AR 066086A1 AR P080101574 A ARP080101574 A AR P080101574A AR P080101574 A ARP080101574 A AR P080101574A AR 066086 A1 AR066086 A1 AR 066086A1
Authority
AR
Argentina
Prior art keywords
nrarb
dihidro
diazepin
ona
sulfonamide
Prior art date
Application number
ARP080101574A
Other languages
English (en)
Inventor
Mcarthur Silvia Gatti
Thomas Johannes Woltering
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR066086A1 publication Critical patent/AR066086A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a compuestos de la formula (1), a un proceso para la obtencion de los mismos, a su utilizacion para la fabricacion de medicamentos destinados a tratar trastornos del SNC y a composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de la formula (1) en la que R1 es H y R2 es -S(O)2-NRaRb o R2 es H y R1 es -S(O)2-NRaRb; R3 H, fluor, cloro, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6 o NRaRb; R4 es cloro, haloalquilo C1-6 o ariloopcionalmente sustituido por halogeno; y Ra y Rb se eligen con independencia entre el grupo formado por H, alquilo C1-6 e hidroxialquilo C2-6; así como las sales farmacéuticamente aceptables del mismo.
ARP080101574A 2007-04-19 2008-04-17 Derivados de dihidro-benzo (b)(1,4)diazepin-2-ona-sulfonamida AR066086A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07106522 2007-04-19

Publications (1)

Publication Number Publication Date
AR066086A1 true AR066086A1 (es) 2009-07-22

Family

ID=39532268

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101574A AR066086A1 (es) 2007-04-19 2008-04-17 Derivados de dihidro-benzo (b)(1,4)diazepin-2-ona-sulfonamida

Country Status (17)

Country Link
US (1) US7511033B2 (es)
EP (1) EP2137167B1 (es)
JP (1) JP2010524879A (es)
KR (1) KR101151993B1 (es)
CN (1) CN101657432B (es)
AR (1) AR066086A1 (es)
AT (1) ATE519751T1 (es)
AU (1) AU2008240802B2 (es)
BR (1) BRPI0810655A2 (es)
CA (1) CA2684760A1 (es)
CL (1) CL2008001083A1 (es)
ES (1) ES2369866T3 (es)
IL (1) IL201198A0 (es)
MX (1) MX2009010729A (es)
PE (1) PE20090148A1 (es)
TW (1) TW200904448A (es)
WO (1) WO2008128889A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
CA2847247C (en) * 2011-08-29 2019-10-15 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
KR20160080799A (ko) 2014-12-30 2016-07-08 한국해양과학기술원 금 촉매를 이용한 α-피론 유도체 전합성 방법 및 이에 의해 합성되어 인간 암세포주에 세포독성을 가지는 α-피론 유도체
CN106243050B (zh) * 2016-08-10 2019-09-06 安徽恒星制药有限公司 一种适合工业化生产氯巴占的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032775A (ja) 1983-07-30 1985-02-19 Daikin Ind Ltd 含フッ素ベンゾジアゼピン類
GB8601004D0 (en) 1986-01-16 1986-02-19 Fujisawa Pharmaceutical Co 1,5-benzodiazepine derivatives
GB9018601D0 (en) 1990-08-24 1990-10-10 Fujisawa Pharmaceutical Co Tricyclic compounds
CA2054455A1 (en) 1990-11-23 1992-05-24 John James Delany Substituted-2,3-dihydro-2-oxo-1,5-benzodiazepines and their use as fungicides
AU671477B2 (en) 1992-07-29 1996-08-29 Merck Sharp & Dohme Limited Benzodiazepine derivatives
GB9314981D0 (en) * 1993-07-20 1993-09-01 Glaxo Spa Chemical compounds
WO1996005818A1 (en) 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
AU6514296A (en) 1995-07-31 1997-02-26 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
CZ292327B6 (cs) * 1995-09-07 2003-09-17 F. Hoffmann-La Roche Ag Derivát 4-(oxyalkoxyfenyl)-3-oxypiperidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
NZ505207A (en) 1997-11-21 2003-10-31 Nps Pharma Inc Metabotropic glutamate receptor antagonists for treating central nervous system diseases
EP1210338A2 (en) 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
WO2001029011A2 (en) * 1999-10-15 2001-04-26 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
ATE261945T1 (de) 1999-10-15 2004-04-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
WO2002083665A1 (en) * 2001-04-12 2002-10-24 F. Hoffmann-La Roche Ag DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I
HUP0400851A3 (en) * 2001-04-12 2010-03-29 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists ii, process for their preparation and pharmaceutical compositions containing them
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives

Also Published As

Publication number Publication date
BRPI0810655A2 (pt) 2014-11-04
CN101657432A (zh) 2010-02-24
US20080261957A1 (en) 2008-10-23
EP2137167A1 (en) 2009-12-30
AU2008240802A1 (en) 2008-10-30
ATE519751T1 (de) 2011-08-15
MX2009010729A (es) 2009-10-26
WO2008128889A1 (en) 2008-10-30
KR20100005715A (ko) 2010-01-15
EP2137167B1 (en) 2011-08-10
CL2008001083A1 (es) 2008-10-24
IL201198A0 (en) 2010-05-17
US7511033B2 (en) 2009-03-31
CN101657432B (zh) 2013-04-10
KR101151993B1 (ko) 2012-06-01
TW200904448A (en) 2009-02-01
AU2008240802B2 (en) 2012-07-05
PE20090148A1 (es) 2009-02-26
JP2010524879A (ja) 2010-07-22
CA2684760A1 (en) 2008-10-30
ES2369866T3 (es) 2011-12-07

Similar Documents

Publication Publication Date Title
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CR10614A (es) Derivados heterociclicos fusionados y metodos de uso
DOP2010000148A (es) Derivados bis-(sulfonilzmino) en terapia 066
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
CU20090184A7 (es) Compuestos amino-heterocíclicos
UY30804A1 (es) Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY31546A1 (es) Derivados bis-(sulfonilamino) en terapia 205
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
CU24327B1 (es) Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CO6260069A2 (es) Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa
UY30938A1 (es) Derivados de nicotinamida, sales y solvatos farmacéuticamente aceptables, composiciones y aplicaciones.
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
ECSP088257A (es) Derivados de amida
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
AR066086A1 (es) Derivados de dihidro-benzo (b)(1,4)diazepin-2-ona-sulfonamida
AR061560A1 (es) Derivados de fenil-metanona sustituidos, proceso de obtencion y medicamentos que los contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure